Ashley M Crane1,2, Roy C Levitt1,3,4,5, Elizabeth R Felix1,6, Konstantinos D Sarantopoulos1,3, Allison L McClellan1, Anat Galor1,2. 1. Miami Veterans Administration Medical Center, Miami, Florida, USA. 2. Department of Ophthalmology, Bascom Palmer Eye Institute, University of Miami, Miami, Florida, USA. 3. Department of Anesthesiology, Perioperative Medicine and Pain Management, University of Miami Miller School of Medicine, Miami, Florida, USA. 4. John P. Hussman Institute for Human Genomics, University of Miami Miller School of Medicine, Miami, Florida, USA. 5. John T Macdonald Foundation Department of Human Genetics, University of Miami Miller School of Medicine, Miami, Florida, USA. 6. Department of Physical Medicine and Rehabilitation, University of Miami Miller School of Medicine, Miami, Florida, USA.
Abstract
OBJECTIVE: To study chronic pain and mental health profiles in patients with dry eye (DE) symptoms, comparing those with high and low levels of neuropathic ocular pain (NOP) complaints. DESIGN: Cross-sectional study of 181 patients with DE symptoms (dry eye questionnaire score ≥6) seen in the Miami Veterans Affairs eye clinic. An evaluation was performed consisting of questionnaires regarding DE symptoms, NOP complaints (burning, sensitivity to wind, light and cold/hot temperatures) and pain elsewhere in the body (non-ocular). This was followed by a comprehensive ocular surface examination. The patients' comorbidities, medications, mental health (depression and post-traumatic stress disorder) and quality-of-life indices were also obtained. Patients were classified using cluster analysis into either the 'high NOP' or 'low NOP' group. Subsequent analyses were performed to examine differences in ocular and non-ocular parameters between these two groups. RESULTS: Despite similar ocular surface findings, patients in the high NOP group had very different systemic (non-ocular) profiles with higher overall pain intensity ratings, higher frequency of comorbid chronic centralised pain conditions, lower quality-of-life indices and more abnormal mental health scores than those in the low NOP group. CONCLUSIONS: Consistent with a chronic overlapping pain condition, patients with DE disease with more severe NOP symptoms report more frequent and severe non-ocular functional comorbid pain disorders. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/.
OBJECTIVE: To study chronic pain and mental health profiles in patients with dry eye (DE) symptoms, comparing those with high and low levels of neuropathic ocular pain (NOP) complaints. DESIGN: Cross-sectional study of 181 patients with DE symptoms (dry eye questionnaire score ≥6) seen in the Miami Veterans Affairs eye clinic. An evaluation was performed consisting of questionnaires regarding DE symptoms, NOP complaints (burning, sensitivity to wind, light and cold/hot temperatures) and pain elsewhere in the body (non-ocular). This was followed by a comprehensive ocular surface examination. The patients' comorbidities, medications, mental health (depression and post-traumatic stress disorder) and quality-of-life indices were also obtained. Patients were classified using cluster analysis into either the 'high NOP' or 'low NOP' group. Subsequent analyses were performed to examine differences in ocular and non-ocular parameters between these two groups. RESULTS: Despite similar ocular surface findings, patients in the high NOP group had very different systemic (non-ocular) profiles with higher overall pain intensity ratings, higher frequency of comorbid chronic centralised pain conditions, lower quality-of-life indices and more abnormal mental health scores than those in the low NOP group. CONCLUSIONS: Consistent with a chronic overlapping pain condition, patients with DE disease with more severe NOP symptoms report more frequent and severe non-ocular functional comorbid pain disorders. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/.
Authors: Michael Costigan; Inna Belfer; Robert S Griffin; Feng Dai; Lee B Barrett; Giovanni Coppola; Tianxia Wu; Carly Kiselycznyk; Minakshi Poddar; Yan Lu; Luda Diatchenko; Shad Smith; Enrique J Cobos; Dmitri Zaykin; Andrew Allchorne; Edith Gershon; Jessica Livneh; Pei-Hong Shen; Lone Nikolajsen; Jaro Karppinen; Minna Männikkö; Anthi Kelempisioti; David Goldman; William Maixner; Daniel H Geschwind; Mitchell B Max; Ze'ev Seltzer; Clifford J Woolf Journal: Brain Date: 2010-08-18 Impact factor: 13.501
Authors: John A Gonzales; Annie Chou; Jennifer R Rose-Nussbaumer; Vatinee Y Bunya; Lindsey A Criswell; Caroline H Shiboski; Thomas M Lietman Journal: Am J Ophthalmol Date: 2018-04-12 Impact factor: 5.258
Authors: Harrison Dermer; Daniella Lent-Schochet; Despoina Theotoka; Christian Paba; Abdullah A Cheema; Ryan S Kim; Anat Galor Journal: Drugs Date: 2020-04 Impact factor: 9.546
Authors: Tina B McKay; Yashar Seyed-Razavi; Chiara E Ghezzi; Gabriela Dieckmann; Thomas J F Nieland; Dana M Cairns; Rachel E Pollard; Pedram Hamrah; David L Kaplan Journal: Prog Retin Eye Res Date: 2018-11-16 Impact factor: 21.198
Authors: Lindsey C McKernan; Leslie J Crofford; Ahra Kim; Simon N Vandekar; William S Reynolds; Kathryn A Hansen; Daniel J Clauw; David A Williams Journal: Pain Med Date: 2021-10-08 Impact factor: 3.750